Dashboard
1
With ROE of 23.47%, it has a Very Expensive valuation with a 5.31 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -1.81%, its profits have fallen by -10.6%
2
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
EUR 2,995 Million (Mid Cap)
23.00
NA
168.66%
0.01
23.47%
5.31
Revenue and Profits:
Net Sales:
160 Million
(Quarterly Results - Jun 2025)
Net Profit:
22 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
2.81%
0%
2.81%
6 Months
9.31%
0%
9.31%
1 Year
-1.5%
0%
-1.5%
2 Years
9.21%
0%
9.21%
3 Years
70.17%
0%
70.17%
4 Years
-6.67%
0%
-6.67%
5 Years
68.24%
0%
68.24%
Laboratorios Farmaceúticos Rovi SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
13.66%
EBIT Growth (5y)
24.84%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0.12
Net Debt to Equity (avg)
0.13
Sales to Capital Employed (avg)
1.34
Tax Ratio
22.85%
Dividend Payout Ratio
28.30%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
36.67%
ROE (avg)
28.59%
Valuation key factors
Factor
Value
P/E Ratio
23
Industry P/E
Price to Book Value
5.31
EV to EBIT
17.82
EV to EBITDA
15.23
EV to Capital Employed
4.77
EV to Sales
4.11
PEG Ratio
NA
Dividend Yield
168.66%
ROCE (Latest)
26.76%
ROE (Latest)
23.47%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
159.70
178.20
-10.38%
Operating Profit (PBDIT) excl Other Income
34.80
44.00
-20.91%
Interest
0.70
0.30
133.33%
Exceptional Items
0.00
-0.00
Consolidate Net Profit
21.60
29.40
-26.53%
Operating Profit Margin (Excl OI)
171.40%
208.60%
-3.72%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is -10.38% vs -0.56% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -26.53% vs 53.12% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
763.70
829.50
-7.93%
Operating Profit (PBDIT) excl Other Income
206.70
243.80
-15.22%
Interest
2.40
0.90
166.67%
Exceptional Items
0.00
0.00
Consolidate Net Profit
136.90
170.30
-19.61%
Operating Profit Margin (Excl OI)
234.00%
264.60%
-3.06%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -7.93% vs 1.44% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -19.61% vs -14.72% in Dec 2023
About Laboratorios Farmaceúticos Rovi SA 
Laboratorios Farmaceúticos Rovi SA
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






